RESEARCH PAPER

Beyond Antibiotics: Solving the UTI Diagnosis and Treatment Puzzle

Priyadarshini. KOYYA[1] *, Naga Bharathi .MARNI[2], Praveena .YEMPADA[3], Devi. Nallajarla[2], Narsin Mohammad[1], Rachel MUTHABATHULA[1], Anusha MODALAVALASA[1] and Varshini MATHALA[1]

[1]*Department of Pharmacy Practice,Vignan Institute of Pharmaceutical Technology (A),Vishakapatnam, Andhra Pradesh.,India.530049*
[2]*Department of Pharmacology, Vignan Institute of Pharmaceutical Technology(A),Visakhapatnam, Andhra Pradesh, India.530049*
[3]*Department of Pharmacognosy, Avanthi Institute of Pharmaceutical Sciences(A), Vizianagaram, Andhra Pradesh, India.531162*
Corresponding Author:
K.Priyadarshini
Assistant Professor, Department of Pharmacy Practice, Vignan Institute of Pharmaceutical Technology (A), Vishakapatnam, Andhra Pradesh., India.530049
E-mail: koyya.priyareddy@gmail.com

Received: 28th Feb, 2026; Revised: 6th March 2026; Accepted: 7th April, 2026; Available Online: 20th April, 2026

ABSTRACT
Urinary tract infections (UTIs) represent a burgeoning global health crisis, with annual cases exceeding 4.49 billion and escalating antimicrobial resistance undermining conventional treatment paradigms. This narrative review synthesizes contemporary evidence advocating a fundamental shift from antibiotic-centric models toward integrated, host-centered management strategies. We examine the complex pathophysiology underlying UTIs, emphasizing the roles of intracellular bacterial communities, urobiome dysbiosis, and gut-bladder axis disruption in driving recurrence. Critical diagnostic limitations of standard urine culture are highlighted, alongside emerging molecular technologies including multiplex PCR, metagenomic sequencing, and host-response biomarkers that enable precision differentiation between colonization and active infection. The antimicrobial resistance crisis is examined, with resistance rates exceeding 50% for foundational agents, necessitating urgent stewardship interventions. We comprehensively evaluate non-antibiotic therapeutic alternatives, including methenamine hippurate, anti-adhesive mannosides, mucosal vaccines like MV140, bacteriophage therapy, and microbiota transplantation protocols. Evidence-based preventive strategies encompassing hydration optimization, cranberry supplementation, and targeted probiotics are discussed alongside specialized management approaches for vulnerable populations including elderly, pediatric, and pregnant patients. Future directions emphasize integrating multi-omics technologies, artificial intelligence-driven diagnostics, and multidisciplinary care models prioritizing ecological restoration over indiscriminate pathogen eradication. This paradigm shift toward precision medicine, antimicrobial stewardship, and microbiome preservation offers sustainable solutions for disrupting recurrence cycles while safeguarding future therapeutic efficacy in an era of diminishing antibiotic utility.

Keywords: *Urinary Tract Infection; Antimicrobial Resistance; Human Microbiome; Precision Medicine; Non-antibiotic therapy;*
How to cite this article: Koyya P, Marni NB, Yempada P, Nallajarla D, Mohammad N, Muthabathula R, Modalavalasa A, Mathala V. Beyond Antibiotics: Solving the UTI Diagnosis and Treatment Puzzle. Int J Drug Deliv Technol. 2026;16(46s): 544-550. DOI: 10.25258/ijddt.16.46s.59

Source of support: Nil.
Conflict of interest: None

INTRODUCTION

Urinary tract infections (UTIs) have transitioned from common clinical encounters to a substantial global health burden. Recent epidemiological data report an annual global case count of 4.49 billion, representing a 66.45% increase since 1990 and an age-standardized incidence rate of 5,531.88 per 100,000 individuals [1]. Although women historically experience the highest burden, with 50–60% reporting at least one symptomatic episode, incidence patterns now show rising rates among older adults and a reversal of previously declining pediatric trends [2,3]. Beyond epidemiological metrics, UTIs impose significant socioeconomic and psychological costs. Patients with recurrent infections incur substantial productivity losses, averaging more than three days of annual sick leave, and frequently work through acute symptoms, sustaining a documented "cost of resignation" [4]. This chronic clinical uncertainty also compromises mental health; approximately 70% of affected individuals report depressive symptoms, elevated anxiety, and sexual

**Author for Correspondence: koyya.priyareddy@gmail.com*

dysfunction that collectively reduce quality of life. Geographical disparities further complicate management, as regions with low sociodemographic indices consistently report the highest incidence and mortality rates, often compounded by environmental conditions that facilitate bacterial transmission [5].

Conventional UTI management has historically depended on broad-spectrum antibiotics to rapidly eliminate pathogens. This approach is no longer sustainable. Rising multidrug resistance and antibiotic-induced dysbiosis in the gut and vaginal microbiota have established a cycle of ecological disruption and reinfection [6,7]. Furthermore, outpatient UTI prescriptions drive community-acquired Clostridioides difficile infections, demonstrating the urgent need for targeted alternatives [8]. This narrative review synthesizes current evidence supporting a paradigm shift toward precision diagnostics, microbiome restoration, immunomodulation, and novel molecular therapies. By evaluating current diagnostic limitations and ecological interventions, this review establishes a clinical framework for transitioning from antibiotic-dependent care to a host-centered model that prioritizes diagnostic accuracy, microbial homeostasis, and antimicrobial stewardship [9,10]. Integrating advanced molecular diagnostics with non-antibiotic therapies will disrupt recurrence cycles, preserve commensal microbiota, and protect long-term antimicrobial efficacy [11,12].

Pathophysiology

UTI pathophysiology involves complex interactions among microbial virulence, host immunity, and local ecological dynamics, rather than simple transient bacterial invasion. Although *Escherichia coli* causes 65–75% of uncomplicated cases, molecular diagnostics reveal a broader uropathogen spectrum [13]. Fastidious organisms such as *Actinotignumschaalii* and *Aerococcusurinae*, frequently missed by standard cultures, contribute to this diversity. Polymicrobial infections constitute approximately 25% of positive cultures. Synergistic species interactions within shared biofilms increase virulence and reduce antimicrobial susceptibility [14]. In immunocompromised patients, viral and fungal etiologies further expand the diagnostic challenge.

Host susceptibility depends on bacterial adhesion capacity and innate urothelial defense mechanisms. Urothelial cells detect bacterial lipopolysaccharide and flagellin via Toll-like receptors (TLR4 and TLR5), which trigger pro-inflammatory signaling cascades [15]. Receptor polymorphisms correlate with increased infection risk. Concurrently, antimicrobial peptides including cathelicidin (LL-37) and defensins mediate direct chemical defense[16]. Patients with recurrent UTIs show reduced urinary LL-37 levels, confirming its role in mucosal immunity. Adaptive immunity relies on IL-17 signaling and bladder tissue-resident memory T (TRM) cells to clear pathogens rapidly. Impaired TRM cell function drives the recurrence cycles observed in susceptible patients.

The urobiome and gut-bladder axis further regulate infection susceptibility. A healthy urinary tract hosts microbial communities primarily stabilized by *Lactobacillus* species, which lower pH and produce protective metabolites [11]. Dysbiosis disrupts this stability, facilitating opportunistic pathogen colonization and ascension. The intestinal tract serves as the primary reservoir for uropathogens[7]. Conventional antibiotics often clear bladder pathogens but fail to eliminate intestinal reservoirs, enabling persistent bacterial translocation and symptomatic reinfection. Patients with recurrent UTIs also exhibit gut microbiome depletion, particularly reduced butyrate-producing taxa that regulate systemic inflammation. Intracellular bacterial communities (IBCs) and established biofilms further shield pathogens from immune clearance and antimicrobial penetration [17]. These pathophysiological mechanisms explain the limitations of conventional eradication therapy and support targeted, microbiome-preserving interventions.

Diagnostic Challenges and Evolving Tools

Standard urine culture, a mid-20th-century aerobic protocol, remains the diagnostic cornerstone for urinary tract infections (UTIs) but fails to distinguish pathogenic infection from commensal colonization within the native urobiome[18]. The assay predominantly isolates rapid-growing aerobes while missing fastidious or slow-growing organisms, including Actinotignumschaalii, Aerococcusurinae, and Streptococcus anginosus[18]. Arbitrary colony-count thresholds further exclude symptomatic patients with low bacterial burdens. Combined with a 24-hour turnaround, these limitations compel empirical prescribing and increase the risk of inappropriate therapy. In vulnerable populations (infants, older adults, catheterized patients), high false-negative rates complicate differentiation between active infection and asymptomatic bacteriuria [18].

Emerging molecular and phenotypic platforms address these limitations by delivering rapid, high-resolution pathogen identification. Multiplex PCR assays detect multiple uropathogens and resistance markers within hours, outperforming traditional culture in sensitivity and reliably resolving polymicrobial infections frequently misclassified as contamination. Culture-independent metagenomic next-generation sequencing (mNGS) identifies rare pathogens (e.g., Mycobacterium tuberculosis) and maps complex resistance determinants directly from clinical specimens [19]. Point-of-care diagnostics leverage loop-mediated isothermal amplification (LAMP) to detect E. coli with >95% accuracy without thermocycling. Concurrently, rapid phenotypic antimicrobial susceptibility testing reduces turnaround times to under six hours, enabling same-day targeted therapy.

Diagnostic accuracy further improves when microbial detection integrates host-response biomarkers. Quantifying urinary inflammatory mediators—including neutrophil gelatinase-associated lipocalin (NGAL), interleukin-6 (IL-6), and interleukin-8 (IL-8)—distinguishes active mucosal inflammation from asymptomatic colonization [20]. Urinary NGAL specifically localizes infection site, differentiating upper from lower tract involvement with >90% accuracy

[20]. A consensus biomarker panel (requiring ≥2 positive indicators) reliably confirms active disease, particularly when culture and molecular results diverge [20]. Integrating pathogen detection with host phenotyping enables a precision medicine framework that accelerates intravenous-to-oral therapy transitions, reduces avoidable hospitalizations, and strengthens antimicrobial stewardship [6]

The Crisis of Antimicrobial Resistance in UTIs

Rapidly escalating antimicrobial resistance (AMR) now compromises standard empirical therapies for urinary tract infections (UTIs). Global Antimicrobial Resistance and Use Surveillance System (GLASS) data report that >40% of Escherichia coli and 55% of Klebsiella pneumoniae isolates resist third-generation cephalosporins. A systematic review encompassing literature through 2025 confirms pooled resistance rates of 52.4% to ciprofloxacin, 49.1% to cephalosporins, and 33.6% to trimethoprim-sulfamethoxazole [21]. Regional cohorts report ampicillin resistance exceeding 91%, while extended-spectrum β-lactamase (ESBL) production drives multidrug-resistant phenotypes in up to 82.8% of isolates globally [22].

Clinical prescribing practices and systemic vulnerabilities drive this resistance escalation. Delayed diagnostics necessitate empirical prescribing, which frequently selects inappropriate agents. Non-prescription antibiotic dispensing accounts for up to 67% of urban use, and 42% of emergency department UTI prescriptions deviate from clinical guidelines [23]. Pandemic-related antibiotic overuse further accelerated resistance dissemination [24]. International travel also disseminates resistant Enterobacterales; travelers colonized in low- and middle-income countries establish persistent community reservoirs.

AMR significantly worsens clinical outcomes and healthcare costs. Infections with resistant uropathogens increase mortality risk 1.5-fold and prolong hospitalization by an average of 2.45 days [25]. Empirical treatment failures increase per-patient expenditures to $1,369, compared to $482 for targeted regimens [26]. Treatment escalation subsequently requires broader-spectrum or last-line agents, which elevate adverse event rates and select for further resistance. Globally, AMR-associated economic losses are projected to reach $16.7 trillion by 2050 [27]. Sustained reliance on empirical antibiotics accelerates resistance and disrupts commensal microbiota, rendering this model unsustainable [12]. Furthermore, outpatient UTI prescriptions directly increase community-acquired Clostridioides difficile infections, demonstrating the clinical and ecological risks of conventional antimicrobial dependence [8].

Rethinking Treatment: Strategies Beyond Conventional Antibiotics

The antimicrobial resistance (AMR) crisis has rendered empiric broad-spectrum antibiotic therapy for urinary tract infections (UTIs) increasingly unsustainable. Contemporary management requires a stewardship-driven framework emphasizing diagnostic precision, targeted drug selection, and optimized treatment durations. The 2024 AUA and 2025 IDSA guidelines replace anatomical classifications with symptom-based stratification [28]. Uncomplicated UTI (uUTI) is restricted to localized bladder infection without systemic illness; baseline comorbidities (e.g., poorly controlled diabetes, non-obstructive anomalies) no longer trigger automatic complicated UTI (cUTI) designation. cUTI now requires documented systemic involvement, bacteremia, renal parenchymal infection, or indwelling devices. This stratification minimizes inappropriate broad-spectrum parenteral therapy. For empiric selection, guidelines mandate assessment of clinical severity, resistance risk factors, pharmacokinetic constraints, and local antibiograms. Aggressive IV-to-oral transition protocols reduce catheter-associated complications and hospitalization duration. Standardized 10–14-day regimens have been replaced by shorter courses. Evidence supports 5–7-day fluoroquinolone regimens and ≤7-day non-fluoroquinolone courses, which maintain clinical cure rates without increasing recurrence within 180 days [28].

Continuous antibiotic prophylaxis drives microbiome depletion and resistance selection, prompting clinical evaluation of non-antibiotic alternatives. Methenamine hippuratehydrolyzes to formaldehyde in acidic urine, denaturing bacterial proteins across multiple targets without selecting for acquired resistance. The ALTAR non-inferiority trial demonstrated methenamine hippurate is non-inferior to daily low-dose antibiotics over 12 months for women with recurrent UTI (rUTI) [29]. The antibiotic arm showed higher resistance acquisition to trimethoprim and cephalosporins, whereas the methenamine arm preserved susceptibility, supporting its prophylactic utility. In contrast, clinical evidence does not support dietary supplements for prevention. Despite theoretical competitive inhibition of FimH adhesins, a 2024 randomized trial (n=598) found no significant difference in rUTI prevention between daily D-mannose and placebo over six months [30]. Given inconsistent efficacy and adverse effect reports, guidelines advise against D-mannose for primary prophylaxis. Conversely, FimH-targeted drug design has yielded synthetic mannosides with binding affinities exceeding natural D-mannose by orders of magnitude [31]. Candidates such as GSK3882347 block bacterial adhesion without exerting bactericidal selective pressure, functioning as antibiotic-sparing agents [32].

Host-directed immunomodulation provides targeted alternatives to pathogen-directed eradication. The sublingual whole-cell vaccine MV140 (Uromune), containing heat-inactivated Escherichia coli, Klebsiella pneumoniae, Enterococcus faecalis, and Proteus vulgaris, stimulates systemic and mucosal immunity via oral-associated lymphoid tissue [33]. Clinical studies report significant rUTI rate reductions with favorable safety profiles in high-risk cohorts, including renal transplant recipients. Parallel approaches modulate innate

inflammatory signaling. Targeting interferon regulatory factor 7 (IRF7) with siRNA in preclinical models attenuates hyperinflammatory cascades, protecting renal tissue from immune-mediated damage during pyelonephritis [34]. Augmenting endogenous antimicrobial peptides (AMPs) represents an additional strategy. RNase 4 and RNase 7 lyse pathogen membranes and correlate inversely with rUTI susceptibility; exogenous AMP delivery may restore compromised mucosal barriers [35].

Restoring microbial ecology addresses the gut-bladder axis to interrupt rUTI cycles. Fecal microbiota transplantation (FMT) has expanded beyond refractory Clostridioides difficile treatment to target multidrug-resistant uropathogen intestinal reservoirs. Clinical studies report FMT reduces urinary infectious episodes by 68.1% and extends the infection-free interval [36]. Direct bladder recolonization via urinary microbiota transplantation (UMT) instills screened donor urine to competitively exclude virulent strains and disrupt biofilms [37]. Bacteriophage therapy provides species-specific targeting for chronic, biofilm-embedded infections [38]. Phages produce polysaccharide depolymerases that degrade the extracellular polymeric substance, enhancing antimicrobial penetration [39]. Ongoing Phase I/II trials evaluate personalized multi-phage cocktails in immunocompromised patients, leveraging phage-host coevolution to minimize resistance emergence [40]. Phage therapy maintains a targeted, microbiome-sparing profile despite evolving regulatory frameworks.

Targeted biofilm disruption and advanced delivery systems address recalcitrant infections. Glycoside hydrolases such as Dispersin B cleave poly-N-acetylglucosamine (PNAG) polymers, destabilizing biofilm architecture and enhancing phagocytic clearance [41]. D-amino acids (e.g., D-leucine) disrupt peptidoglycan cross-linking, triggering biofilm disassembly and reducing effective antibiotic concentrations by 2- to 4-fold [42]. Pharmaceutical nanotechnology enhances device-associated infection management. Sub-10 nm metallic nanoparticles penetrate biofilm matrices to induce oxidative stress and membrane disruption, while polymeric catheter coatings inhibit initial bacterial adhesion [43]. Nanocarrier-delivered AMPs synergistically suppress biofilm-associated gene expression and reduce bacterial load [44]. Sequence-specific CRISPR-Cas antimicrobials represent a precision alternative, delivering endonucleases to cleave resistance plasmids without disrupting commensal taxa [45]. Adjunct therapies include vaginal live biotherapeutic products (e.g., Lactin-V) to restore protective lactic acid production and next-generation ExPEC conjugate vaccines targeting conserved surface antigens [46]. Integrating these modalities establishes a multidimensional, pathogen-specific framework that reduces antimicrobial dependence and improves long-term clinical outcomes.

Preventive and Lifestyle-Based Strategies

Behavioral and mechanical interventions form the foundation of non-pharmacological UTI prevention. Increased fluid intake significantly reduces recurrence rates. A randomized trial in premenopausal women demonstrated that an additional 1.5 L of daily water intake decreased annual symptomatic episodes from 3.2 to 1.7 over 12 months[12]. Enhanced diuresis mechanically clears uropathogens before urothelial adherence occurs. Adjunctive hygienic practices, including front-to-back perineal wiping and immediate post-coital voiding, reduce bacterial inoculation. Menstrual product selection also influences urogenital ecology; observational data associate menstrual cup use with lower symptom prevalence than conventional pads or tampons, potentially by preserving native Lactobacillus-dominant flora.

Targeted nutritional and microbial supplementation modulates mucosal defense and bacterial adhesion. Cranberry extracts containing A-type proanthocyanidins competitively inhibit Escherichia coli fimbrial binding to urothelial receptors. Meta-analyses of over 3,000 participants report a 54% relative risk reduction in UTI incidence with consistent cranberry intake, alongside decreased subsequent antibiotic prescriptions [12]. Consequently, major urological guidelines recommend standardized cranberry preparations for motivated patients. Probiotic strategies, particularly intravaginal administration of Lactobacillus crispatus (CTV-05), restore urogenital homeostasis through lactic acid production and hydrogen peroxide secretion. While generic probiotic formulations show inconsistent efficacy due to strain variability, pathogen-specific trials demonstrate significant recurrence reduction [12]. Micronutrient sufficiency further supports mucosal immunity: ascorbic acid lowers urinary pH, creating a suboptimal environment for uropathogen proliferation, while adequate vitamin D status upregulates epithelial cathelicidin expression, strengthening barrier function.

Clinical implementation of these preventive strategies requires structured shared decision-making and integrated digital tools. Aligning evidence-based recommendations with patient preferences reduces unnecessary empiric prescribing and promotes antibiotic-sparing protocols. Standardized decision aids and clinical decision support systems enable clinicians and patients to objectively evaluate recurrence risk, intervention efficacy, and adverse effect profiles. Digital health platforms further enhance preventive care by facilitating symptom tracking, adherence monitoring, and remote pelvic floor rehabilitation. Integrating behavioral, nutritional, and clinical frameworks establishes a scalable, patient-centered model for long-term UTI management and antimicrobial stewardship.

Special Populations and Contexts

UTI epidemiology, clinical presentation, and optimal management strategies vary significantly across demographic groups. Applying uniform protocols to heterogeneous populations frequently results in either overtreatment of asymptomatic colonization or delayed intervention in clinically complex cases. Population-

specific diagnostic criteria and stewardship frameworks are therefore essential.

Recurrent UTIs (rUTIs), defined as ≥2 episodes within 6 months or ≥3 episodes within 12 months, affect 20–40% of women following an initial infection. Recurrent disease significantly impairs quality of life, sexual function, and occupational productivity. The 2025 AUA guidelines direct clinicians away from continuous antibiotic prophylaxis toward targeted, non-antimicrobial strategies that preserve urogenital microbiota and minimize resistance selection [12]. A core stewardship principle requires strict differentiation between true infection and asymptomatic bacteriuria (ASB); bacteriuria without localized symptoms does not warrant antimicrobial therapy.

Age substantially modifies UTI epidemiology and clinical presentation. UTIs rank among the most frequent infections in older women, affecting approximately 7.0 per 100 person-years in community-dwelling populations and rising to 12.8 per 100 person-years in adults aged ≥85 years [47]. In long-term care settings, non-specific geriatric syndromes (e.g., delirium, functional decline) frequently trigger inappropriate empiric prescribing for underlying ASB. To reduce unnecessary antimicrobial exposure, care pathways increasingly integrate standardized diagnostic algorithms and clinical decision support systems (CDSS) tailored to institutional populations.

Pediatric UTIs carry substantial morbidity, primarily due to the risk of renal scarring and progressive chronic kidney disease. The 2025 EAU/ESPU guideline updates prioritize diagnostic accuracy over convenience. Because voided specimens carry high contamination rates in young children, catheterization or suprapubic aspiration remains the reference standard for infants <2 months and for clinically ambiguous cases [47]. Additionally, guidelines mandate renal and bladder ultrasonography within 24 hours of a febrile pediatric UTI to exclude structural uropathies or high-grade vesicoureteral reflux.

Pregnancy alters genitourinary physiology through progesterone-mediated smooth muscle relaxation and mechanical ureteral compression, increasing upper tract susceptibility. Untreated bacteriuria frequently progresses to acute pyelonephritis, significantly elevating risks for maternal sepsis, preterm labor, and low birth weight. Consequently, pregnancy represents the primary clinical indication where routine ASB screening and prompt treatment remain standard of care.

Diagnostic and therapeutic complexity increases in populations with altered mentation, neurological dysfunction, or indwelling devices. In psychiatric and neurologically impaired patients, acute behavioral changes are frequently misattributed to UTIs. Audit data indicate that up to 71.3% of antibiotics prescribed for altered mental status lack clinical justification [48]. Current IDSA guidelines explicitly recommend against screening or treating bacteriuria in patients with psychiatric conditions or dementia when delirium lacks concurrent genitourinary signs. Patients with neurogenic lower urinary tract dysfunction (NLUTD) secondary to spinal cord injury, multiple sclerosis, or cerebral palsy face elevated complication rates due to incomplete bladder emptying and altered host defenses[49,50]. In acute care settings, prolonged indwelling catheterization directly drives catheter-associated UTI (CAUTI) incidence, reinforcing the necessity for strict insertion criteria and early device removal protocols [51].

Future Directions and Integrative Models of Care

Clinical management of urinary tract infections is transitioning from empirical protocols toward stratified, precision-driven frameworks. This shift replaces culture-dependent binary diagnostics with host-specific profiling that integrates longitudinal host-pathogen dynamics [52]. Multi-omics platforms (genomics, transcriptomics, proteomics, metabolomics) characterize host-microbiome interactions at the urothelial interface, while machine learning algorithms augment clinical decision support. By synthesizing patient demographics, localized antibiograms, and laboratory parameters, predictive models rapidly identify pathogens and susceptibility profiles, reducing time to targeted therapy. Concurrently, metabolic profiling tools such as gas chromatography-ion mobility spectrometry enable non-invasive, rapid detection of microbial volatile organic compounds.

The clinical complexity of refractory infections requires specialized, multidisciplinary management rather than isolated primary care. Dedicated complex-UTI clinics, staffed by urologists, clinical microbiologists, and specialized nurses, report 88% treatment success and significant quality-of-life improvements by aligning interventions with longitudinal microbiological data [53]. Integrative management prioritizes microbiome restoration and urothelial resilience over sterile pathogen eradication. In postmenopausal patients, routine mucosal immunoprophylaxis and localized estrogen therapy restore epithelial integrity and stabilize Lactobacillus-dominant flora [12]. Integrating molecular diagnostics with coordinated, multidisciplinary stewardship establishes a scalable, stratified model for long-term UTI management.

CONCLUSION

The clinical management of urinary tract infections is undergoing a permanent, scientifically mandated paradigm shift. Historical reliance on empiric, broad-spectrum antibiotics is wholly unsustainable amid the escalating antimicrobial resistance crisis, necessitating a multifaceted strategy to solve the complex UTI puzzle. Modern stewardship forms the foundation of this transition. By redefining infection classifications based on systemic signs, truncating treatment durations, and curbing inappropriate prescriptions for asymptomatic bacteriuria, clinicians can drastically reduce unnecessary antimicrobial exposure For prophylaxis, validated non-antibiotic agents like methenamine hippurate offer a highly cost-effective alternative to long-term suppressive therapies , while precision FimH antagonists effectively neutralize bacterial pathogenicity without driving evolutionary resistance

Furthermore, shifting focus toward host fortification yields sustainable physiological solutions. Sublingual whole-cell vaccines have successfully established mucosal immunoprophylaxis as a safe, robust preventive strategy . Concurrently, Fecal and Urinary Microbiota Transplantation directly targets deep physiological reservoirs to restore ecological balance For entrenched, device-associated biofilm infections, precision bacteriophage therapy and advanced nanomaterials provide the necessary tools to dismantle microbial strongholds. Recognizing the unique physiological needs of vulnerable populations remains paramount. Ultimately, integrating these diverse modalities through robust interprofessional collaboration will ensure sustainable, patient-centric urological care well into the future.

CONFLICT OF INTEREST:
No conflict of interest

ACKNOWLEDGEMENT
We express our sincere thanks to our college management for providing the necessary facilities to carry out the above review.

REFERENCES

1. Epidemiological trends and predictions of urinary tract infections. *PMCID: PMC11807111*. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11807111/
2. Social and economic burden of recurrent urinary tract infections and quality of life: a patient web-based study (GESPRIT). Available from: https://www.researchgate.net/publication/318664385
3. Global trends in childhood urinary tract infections, 1990–2021: results from the GBD study. *Front Public Health.* 2025. Available from: https://www.frontiersin.org/articles/10.3389/fpubh.2025.1593206
4. Psychosocial burden of recurrent uncomplicated urinary tract infections. *PMCID: PMC9006425*. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9006425/
5. Comprehensive insights into UTIs: from pathophysiology to precision diagnosis and management. *Front Cell Infect Microbiol.* 2024. Available from: https://www.frontiersin.org/articles/10.3389/fcimb.2024.1402941
6. World Health Organization. WHO warns of widespread resistance to common antibiotics worldwide. 2025. Available from: https://www.who.int/news/item/13-10-2025
7. Recurrent UTIs linked to gut microbiome and chronic inflammation. Washington University School of Medicine. Available from: https://medicine.washu.edu/news
8. Reducing risk of *Clostridium difficile* infection and antibiotic use in outpatient UTI treatment. *PMCID: PMC6120184*.
9. Updates in clinical management of recurrent urinary tract infections. *PubMed.* 2025.
10. Oral vaccine for recurrent UTIs as an alternative to antibiotics. University of Oxford. 2024.
11. Emerging technologies for the diagnosis of urinary tract infections: advances in molecular detection and resistance profiling. *PMCID: PMC12524013*.
12. AUA/CUA/SUFU guideline on recurrent uncomplicated urinary tract infections. *J Urol.* 2025.
13. Novel technologies for the diagnosis of urinary tract infections. *J Clin Microbiol.* 2024.
14. Azevedo AS, Almeida C, Melo LF, Azevedo NF. Impact of polymicrobial biofilms in catheter-associated urinary tract infections. *Crit Rev Microbiol.* 2016;43(4):423–439. doi:10.1080/1040841X.2016.1240656
15. Anders HJ, Patole PS. Toll-like receptors recognize uropathogenic *Escherichia coli* and trigger inflammation in the urinary tract. *Nephrol Dial Transplant.* 2005;20(8):1529–1532. doi:10.1093/ndt/gfh922
16. Chromek M, Slamova Z, Bergman P, et al. The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection. *Nat Med.* 2006;12(6):636–641. doi:10.1038/nm1407
17. Delcaru C, Alexandru I, Podgoreanu P, et al. Microbial biofilms in urinary tract infections and prostatitis: etiology, pathogenicity, and combating strategies. *Pathogens.* 2016;5(4):65. doi:10.3390/pathogens5040065
18. Rapid and accurate testing for urinary tract infection. *PMCID: PMC11905368*.
19. Advances in the diagnosis of urinary tract infection: a narrative review. *EUTI Journal.*
20. A precision medicine model for targeted antibiotic therapy in urinary tract infections. *PubMed.* 2025.
21. Artero A, López-Cruz I, Piles L, et al. Fluoroquinolones are useful as directed treatment for complicated UTI in high-resistance settings. *Antibiotics (Basel).* 2023;12(1):183. doi:10.3390/antibiotics12010183
22. Siddiqui F, et al. High burden of multidrug-resistant uropathogenic *Escherichia coli* with preserved susceptibility to nitrofurantoin. *Front Med Health Res.* 2026;4(4):2712.
23. Morgan DJ, et al. Antimicrobial stewardship practices and challenges in Sub-Saharan Africa. *BMC Public Health.* 2024.

24. Addressing multidrug-resistant urinary tract infections in the Balkans. *PMCID: PMC12466347*.
25. Chandra P. Cefepime-enmetazobactam for complicated urinary tract infections. *Indian J Med Res.* 2026;163:183–193. doi:10.25259/IJMR_2073_2025
26. Impact of empirical treatment failure on healthcare utilization in UTIs. *J Manag Care Spec Pharm.* 2025;31(9):879.
27. O'Neill J. Tackling drug-resistant infections globally: final report and recommendations. London: AMR Review; 2016.
28. Infectious Diseases Society of America. Clinical practice guideline on management of complicated urinary tract infections. 2025.
29. Methenamine hippurate compared with antibiotic prophylaxis to prevent recurrent urinary tract infections. *PubMed.*
30. d-Mannose for prevention of recurrent urinary tract infection. *PMCID: PMC11002776*.
31. D-mannoside FimH inhibitors as non-antibiotic alternatives for uropathogenic *Escherichia coli*. *PMCID: PMC8465801*.
32. Discovery of orally bioavailable FmlH lectin antagonists. *PMCID: PMC10994195*.
33. Current scientific advances in vaccines against urinary tract infections. *Microorganisms.*
34. Immunomodulation therapy offers new strategies to treat urinary tract infections. *PMCID: PMC9214477*.
35. Harnessing antimicrobial peptides in infection prevention. *Pediatrics Nationwide.*
36. Fecal microbiota transplant for recurrent urinary tract infections: proof-of-concept study. *PMCID: PMC12484344*.
37. Emerging insights into microbiome therapeutics for urinary tract infections. *EUTI Journal.*
38. The rise and resurgence of phage therapy for urinary tract infections. *EcoSal Plus.*
39. Phages as therapeutic option in multidrug-resistant urinary tract infections. *Acta Biochim Pol.* 2025.
40. ClinicalTrials.gov. Phage therapy for recurrent UTIs in kidney transplant recipients (NCT06409819).
41. Microbial enzymes as anti-biofilm candidates. *PMCID: PMC11664836*.
42. Role of D-amino acids in biofilm eradication. *PMCID: PMC12674760*.
43. Preventing catheter-related infections based on biofilms. *PMCID: PMC11470810*.
44. Nanotechnology targeting biofilm-forming bacteria. *PMCID: PMC11876546*.
45. Bikard D, Euler C, Jiang W, et al. Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. *Nat Biotechnol.* 2014;32(11):1146–1150.
46. Cohen CR, Wierzbicki A, Donders G, et al. Lactobacillus crispatus for prevention of recurrent UTI. *Lancet Infect Dis.* 2023;23(4):456–465.
47. Management of asymptomatic bacteriuria in adult females. *Obstet Gynecol Surv.* 2025;80(12):752–753.
48. Hartlage W, Castillo AY, Escobar ZK, et al. Reducing inappropriate diagnosis and treatment of UTI. *Antimicrob Steward Healthc Epidemiol.* 2025;5:e49.
49. Ginsberg DA, Boone TB, Cameron AP, et al. AUA/SUFU guideline on adult neurogenic lower urinary tract dysfunction. *J Urol.* 2021;206(5):1097–1105.
50. Agency for Clinical Innovation. Spinal cord injury bladder management guide. NSW Government; 2023.
51. Centers for Disease Control and Prevention. Catheter-associated urinary tract infection (CAUTI) events. 2026.
52. Watkins RR, et al. Managing sepsis in the era of precision medicine. *Expert Rev Anti Infect Ther.* 2022;20(6):871–880.
53. Singh C, Yashwant, Gupta AK, Garg V. Formulation development and evaluation of divalproex sodium extended-release tablets. *Int J Drug Deliv Technol.* 2022;12(4):1769–1773. doi:10.25258/ijddt.12.4.46